Autoimmune Disease Therapeutics Market Outlook (2023 to 2033)

The global autoimmune disease therapeutics market is likely to be valued at US$ 71,466.47 million in 2023 and is predicted to secure a moderate-paced CAGR of 5.6% during the forecast period. The market is expected to grow at a value of US$ 123,507.30 million by 2033. A historical CAGR of 3.6% has been recorded during the analysis by Future Market Insights.

It is identified that there are more than 80 different types of autoimmune disorders amongst which multiple sclerosis, IBS, lupus, type 1 diabetes, psoriasis, rheumatoid arthritis, and others are the most common forms of autoimmune diseases.

Attributes Details
Historical Value (2022) US$ 68,410.54 million
Current Year Value (2023) US$ 71,466.47 million
Expected Forecast Value (2033) US$ 123,507.30 million
Historical CAGR (2018 to 2022) 3.6%
Projected CAGR (2023 to 2033) 5.6%

The adoption of autoimmune disease therapeutics insights reveals they are being used as these diseases cause abnormally low activity or overactivity of the immune systems, attacking the body’s own tissues and cells, which need to be treated therapeutically.

It is witnessed that autoimmune diseases decrease the body’s ability to fight foreign agents, and it is more common in women than in men. Therefore, it is anticipated that the autoimmune disease therapeutics market is likely to have significant growth during the forecast period.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Prime Factors Driving And Deterring The Market Growth Of Autoimmune Disease Therapeutics

The global market for autoimmune disease therapeutics is expected to have increased growth in the coming years and there are many factors identified that are likely to bolster the market dynamics in a positive direction.

Besides the propelling factors, a number of challenges are also identified. Let us take an in-depth look at the following drivers and restraints.

DRIVERS:

  • Rising Awareness of Autoimmune Diseases: It is anticipated that there is a growing prevalence of autoimmune diseases that are growing the awareness amongst the populace for adopting autoimmune disease therapeutics, boosting the market size.
  • Growing Research and Development Activities: It is witnessed that there is a growth in research and development activities to foster the use of ideal therapeutics in the market.
  • Emerging Technologies: There are technological advances in screening procedures, wide availability of therapeutics, and a strong presence of pipeline drugs such as baricitinib, certolizumab, secukinumab, and others that are expected to further influence the market growth.
  • Increased Automation: Additionally, the analysis of FMI records increased the automation of laboratories that are leading to a diagnosis of several tests that generate fast and error-free results that further fuel the market growth.

RESTRAINTS:

  • Inadequate Funding: It is identified that in developing countries there are inadequate funds to flourish adequate adoption and setting up of autoimmune disease therapeutics diagnostics.
  • Non-availability of Treatment: It is anticipated that there is a high cost associated with the treatment of autoimmune diseases and their proper treatments are also unavailable in most countries, which is likely to inhibit the market growth.
  • Advent of Alternative Technologies: The analysis of FMI unravels the factor that there are a lot of emerging technologies, which are being used as an alternative to therapeutics and are likely to curb the growth of the autoimmune disease therapeutics market

Regional Outlook

How is North American Autoimmune Disease Therapeutics Market Performing?

North America is projected to dominate the global autoimmune disease therapeutics market during the forecast period. Currently, the region is accountable for 38.3% of the total market share of autoimmune disease therapeutics.

The growth in the North American region can be attributed to:

  • Growing prevalence of various forms of autoimmune disorders in the region.
  • Government initiatives such as the Affordable Care Act and Patient Protection Act are further fueling the growth of the market size of autoimmune disease therapeutics.
  • Increasing healthcare expenditure in this region is also expected to drive the overall autoimmune disease therapeutics market in North America.

Growth Outlook of Europe Autoimmune Disease Therapeutics Market

Europe is projected to have slow-paced growth during the forecast period, yet it will hold a significant share of the market. At present, the European region is accountable for 27.3% of the total market share of autoimmune disease therapeutics.

The growth can be attributed to:

  • Increased penetration of new technologies such as potable diagnostic equipment and novel biomarkers are contributing largely to the market growth of Europe.
  • A large number of lucrative growth opportunities and improving healthcare infrastructure are likely to foster growth in Europe.
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Country-wise Insights

Countries 2022 Value Share in Global Market
United States 33.8%
Germany 5.4%
Japan 4.1%

How is the Strong Regulatory Framework Influencing the United States Autoimmune Disease Therapeutics Market?

The United States has witnessed a significant increase in the prevalence of autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease. While autoimmune diseases are generally uncommon, the National Institutes for Health (NIH) approximates that they have an impact on about 5% to 8% of the population in the United States.

A GlobalData epidemiology analysis focusing on two prevalent autoimmune diseases, namely systemic lupus erythematosus and Sjögren's syndrome, revealed that the United States and the United Kingdom have higher rates of occurrence compared to other nations. This rising prevalence is driving the demand for autoimmune disease therapeutics.

The United States has a significantly high healthcare expenditure rate compared to other countries worldwide. This substantial investment in healthcare infrastructure provides a conducive environment for market growth. The United States maintains a robust regulatory framework for drug approvals and safety monitoring. The United States Food and Drug Administration (FDA) plays a pivotal role in ensuring the quality, safety, and efficacy of autoimmune disease therapeutics, thereby instilling confidence among healthcare professionals and patients.

Is Germany's Robust Healthcare System Boosting the Autoimmune Disease Therapeutics Sector?

The Germany autoimmune disease therapeutics market is experiencing significant growth due to the rising prevalence of autoimmune diseases, advancements in medical technology, and increasing healthcare expenditure. The Multiple Sclerosis Trust reported a global estimate of 2.5 million individuals living with multiple sclerosis in 2020, with Germany having the highest prevalence.

Germany is renowned for its advanced healthcare infrastructure and technological innovations. The country has been at the forefront of developing novel autoimmune disease therapeutics, including targeted biologics and personalized medicine approaches. The integration of technology, such as artificial intelligence and genomic profiling, is enhancing treatment outcomes and propelling market growth.

The increasing collaboration among industry participants in the country has led to the development of numerous products, driving the expansion of the market. In June 2022, Theradiag joined forces with Quotient Ltd, a diagnostics company in the commercial stage, to leverage Quotient's MosaiQ technology and create an advanced autoimmune diagnostics solution.

Are Government Initiatives Driving Innovation in Japan Autoimmune Disease Therapeutics Market?

Japan has experienced a rise in the prevalence of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and inflammatory bowel disease. This trend can be attributed to factors such as an aging population, environmental factors, and changing lifestyles.

Japan has a well-developed healthcare system, and its population enjoys high awareness and access to healthcare services. This facilitates early diagnosis and treatment of autoimmune diseases, leading to better patient outcomes. Additionally, the Japanese government provides comprehensive healthcare coverage, ensuring the affordability of autoimmune disease therapeutics.

The Japanese government has actively promoted research and development in autoimmune disease therapeutics. Funding support, regulatory incentives, and streamlined approval processes have encouraged pharmaceutical companies to invest in innovative treatments, leading to a robust pipeline of drugs in development.

Countries Value CAGR (2023 to 2033)
United Kingdom 3.9%
China 6.8%
India 5.6%

How is Personalized Medicine Revolutionizing the Treatment of Autoimmune Diseases in the United Kingdom?

The United Kingdom has observed a rise in the prevalence of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. According to a recent study, it has been discovered that autoimmune disorders, including type 1 diabetes and rheumatoid arthritis, affect around 10% of the population in the United Kingdom. Factors such as genetic predisposition, environmental factors, and lifestyle changes contribute to the growing burden of autoimmune diseases, thereby driving the demand for therapeutics.

Personalized medicine has gained traction in the United Kingdom, with a focus on tailoring treatment strategies based on individual patient characteristics. The integration of biomarker analysis, genetic testing, and patient profiling enables physicians to optimize therapeutic interventions, leading to better patient outcomes. The United Kingdom government has also implemented initiatives to address autoimmune diseases' burden and improve patient care.

Can Digital Healthcare Innovations Improve Access to Autoimmune Disease Treatment in China?

The China autoimmune disease therapeutics market has witnessed significant growth over the past few years. In China, the prevalence of autoimmune diseases has been on the rise due to factors such as changing lifestyles, environmental factors, and genetic predisposition. This has created a substantial market for autoimmune disease therapeutics in the country.

There is a shift toward the adoption of biologic therapies for autoimmune diseases in China. Biologics offer targeted treatment options with improved efficacy and reduced side effects compared to conventional therapies. The demand for biologics is expected to increase further in the coming years.

Chinese traditional medicine practices, such as acupuncture and herbal remedies, are being integrated with conventional therapies for autoimmune diseases. This integration provides holistic treatment options and is favored by a significant portion of the population in China.

The rapid growth of digital healthcare in China presents opportunities for autoimmune disease therapeutics. Telemedicine, remote monitoring, and digital health platforms provide innovative ways to improve patient outcomes and enhance access to care.

Is India Ready to Address the Rising Prevalence of Autoimmune Diseases with Effective Therapeutics?

India has witnessed a surge in the prevalence of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and psoriasis, among others. In contemporary times, autoimmune diseases, which were previously deemed uncommon, have emerged as one of the leading contributors to chronic illnesses in India. The growing incidence of these diseases can be attributed to various factors such as genetic predisposition, environmental triggers, and lifestyle changes. This trend has created a significant demand for autoimmune disease therapeutics in the country.

The Indian government has taken several initiatives to improve healthcare access and affordability in the country. Initiatives such as the National Health Policy and Ayushman Bharat have the potential to impact the India autoimmune disease therapeutics market positively. These programs aim to provide universal health coverage and improve access to essential medicines, including those for autoimmune diseases

Segment Wise Analysis

Segment 2022 Value Share in Global Market
Anti-inflammatory Drug Class Type 43.1%
Hospital Pharmacy Sales Channel 77.2%

Are Anti-inflammatory Drugs the Ultimate Solution for Autoimmune Diseases?

The dominance of the anti-inflammatory drug class in the autoimmune disease therapeutics market can be attributed to various factors:

  • These drugs effectively suppress or modulate the immune response, reducing inflammation and alleviating symptoms associated with autoimmune diseases
  • Anti-inflammatory drugs have broad applicability across different autoimmune conditions, as many diseases share common pathways of inflammation
  • These drugs have a long history of clinical use and proven effectiveness in managing autoimmune diseases, giving them an advantage over newer drug classes. The high prevalence of autoimmune diseases further drives the demand for anti-inflammatory therapies
  • The market for these drugs is mature, with a wide range of treatment options available, reflecting substantial investments in research and development

How Have Hospital Pharmacies Gained a Stronghold in the Autoimmune Disease Therapeutics Market?

Hospital pharmacies are likely to play a significant role in the distribution of autoimmune disease therapeutics for several reasons:

  • They are well-equipped to handle specialized medications, such as biologics and immunosuppressants, ensuring correct dosage and treatment
  • Hospitals often have multidisciplinary teams to manage complex autoimmune diseases, with pharmacy services supporting comprehensive patient care
  • Hospital pharmacies can provide continuity of care by supplying medications upon discharge and coordinating with outpatient clinics. Their adherence to strict regulatory compliance further ensures quality standards

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Start-up Ecosystem

The start-up companies in the autoimmune disease therapeutics market are intensifying their focus on frequent innovations and indulging themselves in mergers and acquisitions to develop effective therapeutic solutions for the end-users.

Three Start-ups Gaining Traction in The Market

Viela Bio - The USA-based start-up creates a novel therapeutic to treat neuromyelitis optica spectrum disorder, a neuroinflammatory disorder that causes irreversible blindness and paralysis. UPLIZNA targets the aquaporin-4 antibody in adult patients. A combination of immunosuppressive therapies with UPLIZNA helps patients overcome this rare disease with minimal side effects, including urinary tract infections and influenza.

Immundnz - This British start-up develops COMPIT, an in vitro immune response platform to understand responses in autoimmune disorders. The platform is versatile and helps analyze various parameters including cell viability and cytotoxicity. COMPIT consists of a variety of immune and protein assays that are customizable according to any experimental model to study drug immunology or immune safety.

Landos Biopharma - The Swedish start-up is working on novel therapeutic drugs to treat gastrointestinal immune disorders. The start-up’s lead candidate BT-11, an oral therapeutic drug for treating ulcerative colitis, is currently undergoing Phase II clinical trials. BT-11 activates the lanthionine synthetase C-like protein 2 (LANCL2) pathway, which plays a pivotal role in metabolism and immune response.

Competitive Landscape

Key Market Players Revolutionizing the Autoimmune Disease Therapeutics Market

The market players are focusing on organic growth strategies such as product launches, product approvals, and other such patents and events. They are anticipated to have lucrative growth opportunities in the future with rising demand for autoimmune disease drugs in the global market.

Recent Developments

  • In June 2023, AstraZeneca established a promising partnership through an exclusive option and license agreement with Quell Therapeutics. This collaboration aims to advance the development of various engineered T-regulator (Treg) cell therapies, which show great potential for offering curative treatments for both Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD).
  • In January 2023, Researchers at Penn Medicine made progress in creating a personalized treatment for the rare autoimmune condition known as myasthenia gravis (MG). By adopting the groundbreaking chimeric antigen receptor (CAR) T cell therapy, which is commonly employed for treating specific types of cancer, they have found a potential method to address this form of autoimmune disease.
  • In May 2022, the establishment of Nuvig Therapeutics, Inc. was announced. The company aims to develop innovative therapeutics that promote immune homeostasis and effectively address autoimmune diseases while preserving normal immune function. To aid in accomplishing this objective, Nuvig Therapeutics successfully concluded a Series A financing round, securing US$ 47 million.
  • In June 2021, Abata Therapeutics, a newly established company, was announced by Third Rock Ventures. Their primary objective is to leverage the knowledge of regulatory T cells (Tregs) and translate it into groundbreaking therapeutic solutions for patients suffering from progressive multiple sclerosis and other severe autoimmune and inflammatory conditions. The company's inception was supported by Third Rock Ventures and ElevateBio, and they have successfully secured US$95 million in Series A funding.
  • In October 2019, MiroBio, originating from the University of Oxford, emerged as a separate entity with a Series A funding round amounting to US$ 27 million. The company's primary focus is to advance the development of treatments for autoimmune diseases that target specific mechanisms without causing disruption to the overall immune system.
  • Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that is targeting the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer.
  • ImmuneID is a precision immunology company that is using its genome-wide, high-throughput platform to provide a comprehensive understanding of individual immune responses. They are developing targeted immunological-based biologics using a unique oral delivery platform.

Key companies identified are

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.

Key Segments In The Autoimmune Disease Therapeutics Market

By Drug Class Type:

  • Anti-inflammatory
  • Antihyperglycemics
  • NSAIDs
  • Interferons
  • Others

By Indication:

  • Rheumatic Disease
  • Type 1 Diabetes
  • Multiple Sclerosis
  • Inflammatory Bowel Disease
  • Other Indications

By Sales Channel:

  • Hospital Pharmacy
  • Drug Store & Retail Pharmacy
  • Online Store

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • Middle East and Africa
  • Europe

Frequently Asked Questions

How Big is the Autoimmune Disease Therapeutics Market by 2033?

The projected revenue of the market by 2033 is US$ 123,507.30 million.

What is the Autoimmune Disease Therapeutics Market CAGR for 2033?

The market CAGR for 2033 is projected to be 3.6%.

How Big is the Autoimmune Disease Therapeutics Market?

The market is valued at US$ 71,466.47 million in 2023.

Which Region Holds a Significant Share of the Market?

North America holds a substantial market share.

How North American is Responding to the Market Growth?

Increasing prevalence of autoimmune diseases in North America is key driving factor.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class Type, 2023 to 2033

        5.3.1. Anti-inflammatory

        5.3.2. Antihyperglycemics

        5.3.3. NSAIDs

        5.3.4. Interferons

        5.3.5. Others

    5.4. Y-o-Y Growth Trend Analysis By Drug Class Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class Type, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        6.3.1. Rheumatic Disease

        6.3.2. Type 1 Diabetes

        6.3.3. Multiple Sclerosis

        6.3.4. Inflammatory Bowel Disease

        6.3.5. Other Indications

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sales Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Sales Channel , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sales Channel , 2023 to 2033

        7.3.1. Hospital Pharmacy

        7.3.2. Drug Store & Retail Pharmacy

        7.3.3. Online Store

    7.4. Y-o-Y Growth Trend Analysis By Sales Channel , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Sales Channel , 2023 to 2033

8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. U.S.

            9.2.1.2. Canada

        9.2.2. By Drug Class Type

        9.2.3. By Indication

        9.2.4. By Sales Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class Type

        9.3.3. By Indication

        9.3.4. By Sales Channel

    9.4. Key Takeaways

10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class Type

        10.2.3. By Indication

        10.2.4. By Sales Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class Type

        10.3.3. By Indication

        10.3.4. By Sales Channel

    10.4. Key Takeaways

11. Western Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. U.K.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Drug Class Type

        11.2.3. By Indication

        11.2.4. By Sales Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class Type

        11.3.3. By Indication

        11.3.4. By Sales Channel

    11.4. Key Takeaways

12. Eastern Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Drug Class Type

        12.2.3. By Indication

        12.2.4. By Sales Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class Type

        12.3.3. By Indication

        12.3.4. By Sales Channel

    12.4. Key Takeaways

13. South Asia and Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Drug Class Type

        13.2.3. By Indication

        13.2.4. By Sales Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class Type

        13.3.3. By Indication

        13.3.4. By Sales Channel

    13.4. Key Takeaways

14. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug Class Type

        14.2.3. By Indication

        14.2.4. By Sales Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class Type

        14.3.3. By Indication

        14.3.4. By Sales Channel

    14.4. Key Takeaways

15. Middle East and Africa Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug Class Type

        15.2.3. By Indication

        15.2.4. By Sales Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class Type

        15.3.3. By Indication

        15.3.4. By Sales Channel

    15.4. Key Takeaways

16. Key Countries Analysis

    16.1. U.S.

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Class Type

            16.1.2.2. By Indication

            16.1.2.3. By Sales Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Class Type

            16.2.2.2. By Indication

            16.2.2.3. By Sales Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Class Type

            16.3.2.2. By Indication

            16.3.2.3. By Sales Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Class Type

            16.4.2.2. By Indication

            16.4.2.3. By Sales Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Class Type

            16.5.2.2. By Indication

            16.5.2.3. By Sales Channel

    16.6. U.K.

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Class Type

            16.6.2.2. By Indication

            16.6.2.3. By Sales Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Class Type

            16.7.2.2. By Indication

            16.7.2.3. By Sales Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Class Type

            16.8.2.2. By Indication

            16.8.2.3. By Sales Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Class Type

            16.9.2.2. By Indication

            16.9.2.3. By Sales Channel

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Class Type

            16.10.2.2. By Indication

            16.10.2.3. By Sales Channel

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Class Type

            16.11.2.2. By Indication

            16.11.2.3. By Sales Channel

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Class Type

            16.12.2.2. By Indication

            16.12.2.3. By Sales Channel

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Class Type

            16.13.2.2. By Indication

            16.13.2.3. By Sales Channel

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Class Type

            16.14.2.2. By Indication

            16.14.2.3. By Sales Channel

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Class Type

            16.15.2.2. By Indication

            16.15.2.3. By Sales Channel

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Class Type

            16.16.2.2. By Indication

            16.16.2.3. By Sales Channel

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Class Type

            16.17.2.2. By Indication

            16.17.2.3. By Sales Channel

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Class Type

            16.18.2.2. By Indication

            16.18.2.3. By Sales Channel

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Class Type

            16.19.2.2. By Indication

            16.19.2.3. By Sales Channel

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Class Type

            16.20.2.2. By Indication

            16.20.2.3. By Sales Channel

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Class Type

            16.21.2.2. By Indication

            16.21.2.3. By Sales Channel

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2022

            16.22.2.1. By Drug Class Type

            16.22.2.2. By Indication

            16.22.2.3. By Sales Channel

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2022

            16.23.2.1. By Drug Class Type

            16.23.2.2. By Indication

            16.23.2.3. By Sales Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Class Type

        17.3.3. By Indication

        17.3.4. By Sales Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Abbott Laboratories

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. AbbVie Inc.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Amgen Inc.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. AstraZeneca Plc.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Bristol-Myers Squibb Company

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Johnson & Johnson

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Novartis AG

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Pfizer Inc.

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. UCB S.A.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Autoimmune Disease Testing Market

April 2023

REP-GB-16969

324 pages

Healthcare

Kinase Inhibitor in Autoimmune Diseases Market

December 2022

REP-GB-16171

280 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Autoimmune Disease Therapeutics Market